Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  Pheochromocytoma
Results 1-13 of 13 for your search:
Start Over
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients with Primary or Metastatic Gastrointestinal or Pancreatic Neuroendocrine Tumors
Status: Active
Phase: Phase II
Type: Diagnostic
Age: 18 and over
Trial IDs: 13-C-0193, NCI-2014-02318, 335154, NCT01967537
Gallium Ga 68-DOTATATE PET/CT in Diagnosing Patients With Somatostatin-Receptor Positive Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Diagnostic
Age: 19 and over
Trial IDs: NET0017, NCI-2014-01016, 26988, NCI-2014-00101, NCT01980732
Pembrolizumab in Treating Patients with Rare Solid Tumors That Cannot Be Removed by Surgery or are Metastatic
Status: Not yet active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2015-0948, NCI-2016-00545, NCT02721732
Liposomal Irinotecan and Veliparib in Treating Patients with Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
Status: Not yet active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 9914, NCI-2015-02125, NCT02631733
Long-Term Follow up for Patients Previously Enrolled in National Cancer Institute Surgery Branch Studies
Status: Enrolling by invitation
Phase: No phase specified
Type: Natural history/Epidemiology
Age: 16 and over
Trial IDs: 09-C-0161, NCI-2015-01184, 090161, 304795, 344944, P09518, NCT00923026
Molecular Markers in Diagnosing Patients with Adrenal Neoplasms
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis
Age: 18 to 90
Trial IDs: 11-C-0149, NCI-2015-01242, 313454, P11820, NCT01348698
Iobenguane I 131 in Treating Patients with Relapsed or Refractory Neuroblastoma or Metastatic Pheochromocytoma
Status: Active
Phase: No phase specified
Type: Supportive care, Treatment
Age: 1 and over
Trial IDs: 2012LS107, NCI-2013-01933, NCT01850888
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Natural history/Epidemiology
Age: 18 and over
Trial IDs: CGI-061, NCI-2013-01950, NCT02092714
Clinical Manifestations and Genetic Defects in Identifying Disease Causality in Samples From Patients with Heritable Urologic Malignant Disorders
Status: Active
Phase: No phase specified
Type: Genetics, Natural history/Epidemiology
Age: Not specified
Trial IDs: 89-C-0086, NCI-2013-02066, 890086, NCT00019617, NCT00001238
Cabozantinib-s-malate in Treating Patients with Metastatic Pheochromocytomas or Paragangliomas That Cannot Be Removed by Surgery
Status: Active
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 2014-0081, NCI-2014-02607, NCT02302833
Gallium Ga 68-edotreotide PET/CT in Diagnosing Patients with Neuroendocrine Tumors
Status: Enrolling by invitation
Phase: No phase specified
Type: Diagnostic
Age: Not specified
Trial IDs: 14-226, NCI-2015-00286, NCT02358018
Effect of Cabozantinib S-Malate or Lenvatinib Mesylate on Weight and Body Composition in Patients with Metastatic Endocrine Cancer
Status: Active
Phase: No phase specified
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 2014-0864, NCI-2015-02058, NCT02592356
Start Over